Editas Medicine (EDIT) Misses Q4 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Editas Medicine (EDIT) Misses Q4 EPS by 9c

Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update

March 6, 2018 4:01 PM EST

EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing

Expecting at least five clinical-stage programs by end of 2022 as part of EM22 five-year goals

Year-end cash, cash equivalents, and marketable securities of $329 million expected to fund business for at least 24 months

CAMBRIDGE, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today reported financial results for the fourth quarter and full year 2017.  The Company also outlined its recent achievements... More